Abstract
A primary objective of pharmacokinetic-pharmacodynamic (PKPD) reasoning is to identify key in vivo drug and system properties, enabling prediction of the magnitude and time course of drug responses under physiological and pathological conditions in animals and man. Since the pharmacological response generated by a drug is highly dependent on the actual system used to study its action, knowledge about its potency and efficacy at a given concentration or dose is insufficient to obtain a proper understanding of its pharmacodynamic profile. Hence, the output of PKPD activities extends beyond the provision of quantitative measures (models) of results, to the design of future protocols. Furthermore, because PKPD integrates DMPK (e.g. clearance) and pharmacology (e.g. potency),it provides an anchor point for compound selection, and, as such, should be viewed as an important weapon in medicinal chemistry. Here we outline key PK concepts relevant to PD, and then consider real-life experiments to illustrate the importance to the medicinal chemist of data obtained by PKPD. Useful assumptions and potential pitfalls are described, providing a holistic view of the plethora of determinants behind in vitro-in vivo correlations. By condensing complexity to simplicity, there are not only consequences for experimental design, and for the ranking and design of compounds, but it is also possible to make important predictions such as the impact of changes in drug potency and kinetics. In short, by using quantitative methods to tease apart pharmacodynamic complexities such as temporal differences and changes in plasma protein binding, it is possible to target the changes necessary for improving a compounds profile.
Keywords: Mechanism-based PKPD modelling, potency, efficacy, lipophilicity, structure-activity relationship, turnover models, effect compartment models, occupancy binding models
Current Topics in Medicinal Chemistry
Title: Pharmacodynamic-Pharmacokinetic Integration as a Guide to Medicinal Chemistry
Volume: 11 Issue: 4
Author(s): Johan Gabrielsson, Ola Fjellstrom, Johan Ulander, Michael Rowley and Piet H. Van Der Graaf
Affiliation:
Keywords: Mechanism-based PKPD modelling, potency, efficacy, lipophilicity, structure-activity relationship, turnover models, effect compartment models, occupancy binding models
Abstract: A primary objective of pharmacokinetic-pharmacodynamic (PKPD) reasoning is to identify key in vivo drug and system properties, enabling prediction of the magnitude and time course of drug responses under physiological and pathological conditions in animals and man. Since the pharmacological response generated by a drug is highly dependent on the actual system used to study its action, knowledge about its potency and efficacy at a given concentration or dose is insufficient to obtain a proper understanding of its pharmacodynamic profile. Hence, the output of PKPD activities extends beyond the provision of quantitative measures (models) of results, to the design of future protocols. Furthermore, because PKPD integrates DMPK (e.g. clearance) and pharmacology (e.g. potency),it provides an anchor point for compound selection, and, as such, should be viewed as an important weapon in medicinal chemistry. Here we outline key PK concepts relevant to PD, and then consider real-life experiments to illustrate the importance to the medicinal chemist of data obtained by PKPD. Useful assumptions and potential pitfalls are described, providing a holistic view of the plethora of determinants behind in vitro-in vivo correlations. By condensing complexity to simplicity, there are not only consequences for experimental design, and for the ranking and design of compounds, but it is also possible to make important predictions such as the impact of changes in drug potency and kinetics. In short, by using quantitative methods to tease apart pharmacodynamic complexities such as temporal differences and changes in plasma protein binding, it is possible to target the changes necessary for improving a compounds profile.
Export Options
About this article
Cite this article as:
Gabrielsson Johan, Fjellstrom Ola, Ulander Johan, Rowley Michael and H. Van Der Graaf Piet, Pharmacodynamic-Pharmacokinetic Integration as a Guide to Medicinal Chemistry, Current Topics in Medicinal Chemistry 2011; 11 (4) . https://dx.doi.org/10.2174/156802611794480864
DOI https://dx.doi.org/10.2174/156802611794480864 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preconception Counselling: A Five- Year Experience in a Teratology Information Service
Letters in Drug Design & Discovery Glutathione Peroxidase: A Potential Marker for the Most Common Diseases and Disorders
Recent Patents on Biomarkers Apoptosis Following Photodynamic Tumor Therapy: Induction, Mechanisms and Detection
Current Pharmaceutical Design Reviewed and updated Algorithm for Genetic Characterization of Syndromic Obesity Phenotypes
Current Genomics Mechanistic Insights into Aspartame-induced Immune Dysregulation
Current Nutrition & Food Science Bioactive Food Components as Dietary Intervention for Cystic Fibrosis
Current Drug Targets Exercise in a Pill: Feasibility of Energy Expenditure Targets
Current Drug Targets - CNS & Neurological Disorders Design, Synthesis and Biological Evaluation of Ligands Selective for the Melanocortin-3 Receptor
Current Topics in Medicinal Chemistry Contemporary Management of Hypertension - How to Optimize Therapy
Cardiovascular & Hematological Disorders-Drug Targets Are Hormones Relevant for the Search and Design of Anti-Parasitic Drugs?
Current Topics in Medicinal Chemistry AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives
Current Drug Targets Vitiligo in Children: A Birds Eye View
Current Pediatric Reviews Dynamics of Telomere Length in Different Age Groups in a Latvian Population
Current Aging Science The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence
Current Pharmaceutical Design Combination of Irbesartan with Amlodipine Enhances Nitrate/Nitrite Generation by Angiotensin II-exposed Endothelial Cells
Letters in Drug Design & Discovery Wzy-Dependent Bacterial Capsules as Potential Drug Targets
Current Drug Targets Recent Progress in Biomedical Applications of Magnetic Nanoparticles
Recent Patents on Nanotechnology subject Index To Volume 3
Current Protein & Peptide Science Oxidative Stress and Inflammation: Their Role in the Pathogenesis of Peripheral Artery Disease with or Without Type 2 Diabetes Mellitus
Current Vascular Pharmacology Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives
Current Cancer Drug Targets